InformationThere may be additional criteria to what is listed here, speak to your doctor to confirm whether this trial is right for you.Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 2 February 2024

BLOCK PCNSL (NHL32): This phase II study is trying to determine if standard chemotherapy induction therapy followed by immunotherapy (pembrolizumab) will be effective in maintaining life expectancy with minimal side effects for people with primary central nervous system lymphomaAn ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Clinical summary

Summary

All participants in this trial will receive chemotherapy induction therapy (CIT) of either A) Rituximab, Methotrexate, Procarbazine & Vincristine (R-MPV) Cytarabine (Ara-C); or B) Cytarabine, Thiopeta & Rituximab (MATRix). The CIT given is at the discretion of the participant's clinician and is not assessed as part of this study. Once the induction treatment is complete, participants will receive Pembrolizumab immunotherapy (200mg via intravenous infusion) commencing 4-6 weeks after last CIT exposure, and administered every 3 weeks for 35 cycles/2 years.

Conditions

This trial is treating patients with primary central nervous system lymphoma

Cancer

Blood Cancers Haematological

Age

People18+

Phase

II

Trial Acronym

BLOCK PCNSL (NHL32)

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Merck,Australasian Leukaemia and Lymphoma Group (ALLG)

Scientific Title

An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Eligibility

Inclusion

 

Treatment-naïve new diagnosis of PCNSL (DLBCL)
Age = greater than or equal to 18 years
ECOG = less than or equal to 3
Considered appropriate for induction CIT as per investigator
No standard contraindication to immune checkpoint inhibition

Exclusion

Active autoimmune disease
Unfit for induction CIT (prohibitive organ dysfunction)
Non-B-cell lymphoma subtype
Systemic involvement with aggressive lymphoma

Inclusion

  • You have been diagnosed with cancer, but have not received any treatment.

Exclusion

  • You have certain types of non-cancer medical conditions.
Message

There may be additional criteria to what is listed here, speak to your doctor to confirm whether this trial is right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Cancer Connect

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Get support

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

More info for carers

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.